Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Naoto Okada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Yamaguchi University Hospital, Yamaguchi, Japan. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Immune Checkpoint Inhibitors, Pharmacovigilance, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI)‐induced adverse events due to excessive immune stimulation are problematic in immunotherapy. The activation of viral infection triggered by ICI‐induced dysregulated immunity has been proposed; however, this association remains inconsistent. This study investigated the association between ICI administration and cytomegalovirus (CMV) infections, a pathogen linked to immune abnormalities and reactivation, using the Food and Drug Administration Adverse Event Reporting System. We used the crude data set and immunocompromise‐free data set from the fourth quarter of 2012 to 2023. The disproportionality between CMV infection and ICI was analyzed using reporting odds ratio (ROR) and information component (IC) methodologies. Disproportionality between ipilimumab and nivolumab combination case and CMV infection was observed in the crude (ROR: 2.83, 95% confidence interval [CI]: 2.32–3.47; IC: 1.48, 95% CI: 1.14–1.73) and immunocompromise‐free data set (ROR: 1.76, 95% CI: 1.33–2.33; IC: 0.80, 95% CI: 0.33–1.14), whereas disproportionality between other ICI and CMV infection was not observed in the immunocompromise‐free data set. Multiple sensitivity analyses and time‐scan analysis also revealed the consistent disproportionality between ipilimumab and nivolumab combination cases and CMV infection, regardless of the host's immune status. While further research is warranted to validate our findings, these results highlight new insights into ICI‐induced viral infections and suggest the importance of considering the possibility of CMV infections during ipilimumab and nivolumab combination therapy, regardless of the host's immune status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Yamaguchi University Hospital, Yamaguchi, Japan.
- Faculty of Medicine and Health Sciences, Yamaguchi University, Yamaguchi, Japan.
- Clinical Pharmacology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
ORCID-Profile: Naoto Okada
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Okada, N., Yanagi, T., Sasaki, T., Tamura, M., Ozaki, M., Saisyo, A., & Kitahara, T. (2025). Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system. International Journal of Cancer. https://doi.org/10.1002/ijc.35155
Vancouver
Okada N, Yanagi T, Sasaki T, Tamura M, Ozaki M, Saisyo A, et al. Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system. International Journal of Cancer. 2025. doi:10.1002/ijc.35155
BibTeX
@article{Okada2025,
author = {Okada, Naoto and Yanagi, Tomoyuki and Sasaki, Takaaki and Tamura, Miho and Ozaki, Masakazu and Saisyo, Atsuyuki and Kitahara, Takashi},
title = {Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35155}
}
EUVIMED